Drugs / [68Ga]Ga-EVS459
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06376253 | Sep 2024 → Jul 2025 | lung cancer, ovarian cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-EVS459 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06376253 ↗ |
| Modality | Diagnostic / imaging agent | “Radioligand imaging agent” NCT06376253 ↗ |